Zeidler H K, Kvien T K, Hannonen P, Wollheim F A, Førre O, Geidel H, Hafström I, Kaltwasser J P, Leirisalo-Repo M, Manger B, Laasonen L, Markert E R, Prestele H, Kurki P
Medizinische Hochschule Hannover, Division of Rheumatology, Germany.
Br J Rheumatol. 1998 Aug;37(8):874-82. doi: 10.1093/rheumatology/37.8.874.
This study compared the progression of joint damage in patients with early active severe rheumatoid arthritis (RA) treated with cyclosporin or parenteral gold.
In this open, randomized, multicentre study with a blinded radiological endpoint, 375 patients who had suffered from active severe RA for <3 yr were randomized to be treated for 18 months with low-dose cyclosporin or parenteral gold. The groups were stratified with regard to corticosteroid use. Primary efficacy variables were numbers of erosions, erosion score and the Larsen-Dale joint damage score.
Joint damage progressed at similar rates in both treatment arms. In both groups, patients receiving corticosteroids had less X-ray progression. Rheumatoid factor positivity, high swollen joint count, high erythrocyte sedimentation rate and pre-existing X-ray abnormalities predicted progression of joint damage. Although numbers of serious adverse events were similar, more gold patients (n = 65) than cyclosporin patients (n = 45) withdrew from study medication because of adverse events.
Cyclosporin was comparable to parenteral gold in retarding progression of joint damage and was better tolerated in terms of adherence to therapy. The open label design should be kept in mind when assessing this difference.
